Lauryn S. Bracken
St Vincent's Hospital Sydney(AU)
Publications by Year
Research Areas
Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Inflammatory Bowel Disease
Most-Cited Works
- → Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors(2013)132 cited
- → ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling(2015)87 cited
- → AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia(2015)62 cited
- → Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia(2014)54 cited
- → An assessment of the transparency of contemporary technology education research employing interview-based methodologies(2021)20 cited
- → Up-regulation of Survivin during Immortalization of Human Myofibroblasts Is Linked to Repression of Tumor Suppressor p16INK4a Protein and Confers Resistance to Oxidative Stress(2013)10 cited
- → Dual Inhibition of JAK/STAT and MAPK Pathways Results in Synergistic Cell Killing of JAK-Mutated Pediatric Acute Lymphoblastic Leukemia(2012)3 cited
- → Abstract 3276: Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program(2015)3 cited
- → Supplementary Materials and Methods, Supplementary Tables 1 through 9, and Supplementary Figures 1 through 8 from Evaluation of the <i>In Vitro</i> and <i>In Vivo</i> Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia(2023)